Evidence Lacking for Impact of PDMPs on Drug Overdoses

Share this content:
Evidence Lacking for Impact of PDMPs on Drug Overdoses
Evidence Lacking for Impact of PDMPs on Drug Overdoses

TUESDAY, May 8, 2018 (HealthDay News) -- There is insufficient evidence available for examining the correlation between prescription drug monitoring programs (PDMPs) and non-fatal or fatal overdoses, according to a review published online May 8 in the Annals of Internal Medicine.

David S. Fink, M.P.H., from Columbia University in New York City, and colleagues examined whether PDMP implementation correlates with changes in non-fatal and fatal overdoses and identifies features of programs differentially associated with those outcomes. A total of 17 articles met the inclusion criteria and were reviewed.

The articles examined PDMPs only, program features only, PDMP implementation and program features, PDMP implementation with mandated provider review combined with pain clinic laws, and PDMP robustness. The researchers found that three of the studies had insufficient evidence to draw conclusions regarding an association between PDMP implementation and non-fatal overdoses. Based on 10 studies, there was low-strength evidence for a reduction in fatal overdoses with PDMP implementation. A decrease in overdose deaths was seen in association with program features, including mandatory provider review, provider authorization to access PDMP data, frequency of reports, and monitoring of non-scheduled drugs. In three of six studies, after implementation of PDMPs there was an increase in heroin overdoses.

"Evidence that PDMP implementation either increases or decreases non-fatal or fatal overdoses is largely insufficient, as is evidence regarding positive associations between specific administrative features and successful programs," the authors write. "Some evidence showed unintended consequences."

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »